Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection
NCT07010744Enrolling by invitation
- Start
- Jul 2025
- Primary completion
- Jun 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Randomised, open-label trial of amoxicillin, clarithromycin, esomeprazole, bismuth subcitrate, metronidazole and 1 more in Helicobacter pylori infection (2 arms). Primary endpoint: Eradication rate of Helicobacter pylori infection at 1 month. Started Jul 2025; status: enrolling by invitation.
02
Drugs
amoxicillinclarithromycinesomeprazolebismuth subcitratemetronidazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07010744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07010744.